Published in Cancer Weekly, September 10th, 2002
One key weapon in this arsenal of new therapies is called Herceptin, a drug that is currently used to treat breast cancer and works by targeting a specific protein that controls cell growth called HER-2/neu. But despite the drug's effectiveness, tumors shrink in only the small percentage of breast cancer patients whose cancer cells express an overabundance of HER-2/neu.
Now, laboratory studies conducted by researchers at Cedars-Sinai Medical Center and Genentech have found that a potent...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2002-09-10)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.